Abstract: What`s New for 2022? – Global competitiveness and key competitor percentage market shares. – Market presence across multiple geographies – Strong/Active/Niche/Trivial.
New York, May 11, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Acute Myeloid Leukemia (AML) Therapeutics Industry” – https://www.reportlinker.com/p06051402/?utm_source=GNW
– Online interactive peer-to-peer collaborative bespoke updates
– Access to our digital archives and MarketGlass Research Platform
– Complimentary updates for one year
– Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $976.2 Million by 2026
– Leukemias are malignant disorders, the main symptom of which is an abnormally high leucocyte count in the human bone marrow and/or blood. The disease causes a substantial number of deaths worldwide every year. The types of Leukaemia vary by origin, pathogenesis, prognosis, and incidence. The dominant leukemia cells may be mature cells like in chronic lymphocytic leukemia (CLL); acute leukemias with precursor cells of multiple lineages; or both mature and precursor cells like in chronic myeloid leukemia (CML). Among the severe types of leukemia, acute lymphoblastic leukemia (ALL) is often seen in children as also in young adults, particularly in the 2 to 5 years age groups, whereas acute myeloid leukemia (AML) is more commonly seen in adults. Additionally, other rare leukemia types like atypical chronic myeloid leukemia…
